[Serological tests based on viral glycoproteins for detecting neutralizing antibodies to measles, mumps and rubella...

Measles, mumps and rubella viruses are highly contagious viruses that can cause serious clinical outcomes, complications and death. Neutralizing antibodies against measles, mumps and rubella viruses are a good indicator of clinical protection against these infections, but they are difficult to measure.

To develop a serological glycoprotein-based passive hemagglutination reaction (gpPHAR) tests for the detection of neutralizing antibodies to measles, mumps and rubella viruses.

Human and animal cell cultures from the collection of the I.I. Mechnikov Research Institute of Vaccines and Sera were used; vaccine strains of measles, mumps and rubella viruses; monoclonal antibodies to measles and rubella virus glycoproteins, human and animal immune sera; formalized sheep erythrocytes sensitized with viral glycoproteins; virus neuralization test (VNT), gpPHAR and gpELISA.

Viral glycoproteins of measles, mumps, and rubella were extracted from infected cell cultures. Comparative titrations of human and animal immune sera to measles, mumps, and rubella viruses in VNT, gpPHAR, and gpELISA have been performed. Unambiguous titers of neutralizing antibodies have been established. Titration of homologous and heterologous immune sera to three viruses was performed in the gpPHAR. The absence of cross-immunoreactivity to other viral agents has been established. The titers of the immune sera of patients with measles, mumps, and rubella infections were determined in the gpPHAR and gpELISA assays. Identical titers of neutralizing antibodies were found in both serological tests.

The gpPHAR serological tests has been developed to evaluate neutralizing virus-specific antibodies to measles, mumps and rubella in patients.